ATLANTA – About what he called "incredible" data with BB-2121 in multiple myeloma (MM), Bluebird Bio Inc.'s chief medical officer, David Davidson, told BioWorld that his firm is "actually in a privileged position to have positive results across all of our clinical programs" at the scientific meeting, with data in severe sickle cell disease (SCD) and beta-thalassemia. "But clearly the myeloma results are really getting everyone excited," he said.